Acceleron Announces Pricing of Public Offering of Common Stock
05 Enero 2016 - 6:35PM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutic candidates that regulate
cellular growth and repair, today announced that it has priced an
underwritten public offering of 3,750,000 shares of common stock at
a price to the public of $40.00 per share for gross proceeds of
$150 million. In connection with this offering, Acceleron has
granted the underwriters a 30-day option to purchase up to an
additional 562,500 shares of common stock.
Morgan Stanley, Leerink Partners LLC and UBS Investment Bank are
acting as joint book-running managers for the offering. JMP
Securities is acting as the lead manager and FBR is acting as
co-manager for the offering. The offering is expected to close on
or about January 11, 2016, subject to the satisfaction of customary
closing conditions.
Acceleron expects to receive net proceeds from the offering,
after deducting underwriting discounts and commissions and other
offering expenses payable by the company, of approximately $140.4
million. Acceleron intends to use the net proceeds to conduct
clinical trials and associated activities in connection with
ACE-083, Acceleron’s clinical stage therapeutic candidate designed
to promote muscle growth and function in specific, targeted
muscles, and Acceleron’s other potential therapeutic candidates,
including antibodies and proteins from Acceleron’s IntelliTrapTM
platform, to further expand Acceleron’s research and development
efforts, and for general and administrative expenses, potential
future development programs, capital expenditures and working
capital and other general corporate purposes.
The shares are being offered by Acceleron pursuant to an
effective shelf registration statement on Form S-3 that was
previously filed with the Securities and Exchange Commission (the
“SEC”). A preliminary prospectus supplement relating to and
describing the terms of the offering was filed with the SEC on
January 4, 2016. The final prospectus supplement relating to the
offering will be filed with the SEC. When available, copies of the
final prospectus supplement and the accompanying prospectus can be
obtained at the SEC’s website http://www.sec.gov or from Morgan
Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, NY 10014; Leerink Partners LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA,
02110, or by e-mail at Syndicate@Leerink.com, or by phone at
800-808-7525, ext. 6142; or UBS Securities LLC, 1285 Avenue of the
Americas, New York, New York 10019, Attention: Prospectus
Department, or by phone at 1-888-827-7275.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities in the offering, nor
shall there be any sale of these securities in any jurisdiction in
which an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
jurisdiction.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of novel
therapeutic candidates that regulate cellular growth and repair.
The company is a leader in understanding the biology of the
Transforming Growth Factor-Beta (TGF-β) protein superfamily, a
large and diverse group of molecules that are key regulators in the
growth and repair of tissues throughout the human body, and in
targeting these pathways to develop important new medicines.
Acceleron has built a highly productive R&D platform that has
generated innovative clinical and preclinical therapeutic
candidates with novel mechanisms of action. These therapeutic
candidates have the potential to significantly improve clinical
outcomes for patients with cancer and rare diseases.
Cautionary Note on Forward-Looking Statements
Certain statements contained in this release, including those
relating to the use of proceeds from the sale of common stock and
the expected closing of the offering, are forward-looking
statements that involve a number of risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements. These risks and uncertainties include,
but are not limited to: our ability to successfully complete the
offering; the volatility of our stock price may prevent shares
purchased in the offering from being resold at or above the price
paid for them; purchasers of shares in the offering will suffer
immediate and substantial dilution; we may use the proceeds from
the offering in ways that may not enhance our operating results or
the market price of our common stock; and other risk factors
identified from time to time in the reports we file with the SEC,
including our Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K, which are available at
www.sec.gov. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release. The forward-looking statements in this press release speak
only as of the date of this document, and we undertake no
obligation to update or revise any of the statements. Our business
is subject to substantial risks and uncertainties, including those
referenced above. Investors, potential investors, and others should
give careful consideration to these risks and uncertainties.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160105006893/en/
Investors:Acceleron PharmaTodd James, 617-649-9393Senior
Director, Investor Relations and Corporate
CommunicationsorMedia:BMC CommunicationsBrad Miles,
917-570-7340Bmiles@bmccommunications.com
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024